Eli Lilly
2,051 hedge funds and large institutions have $183B invested in Eli Lilly in 2021 Q3 according to their latest regulatory filings, with 133 funds opening new positions, 731 increasing their positions, 799 reducing their positions, and 79 closing their positions.
68% more first-time investments, than exits
New positions opened: 133 | Existing positions closed: 79
1% more funds holding
Funds holding: 2,022 → 2,051 (+29)
1% more capital invested
Capital invested by funds: $182B → $183B (+$1.06B)
0.08% more ownership
Funds ownership: 82.79% → 82.87% (+0.08%)
9% less repeat investments, than reductions
Existing positions increased: 731 | Existing positions reduced: 799
10% less funds holding in top 10
Funds holding in top 10: 61 → 55 (-6)
28% less call options, than puts
Call options by funds: $1.34B | Put options by funds: $1.86B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$868M |
| 2 |
Two Sigma Advisers
New York
|
+$493M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$371M |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$300M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$298M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$530M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$522M |
| 3 |
JP Morgan Chase
New York
|
-$360M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$343M |
| 5 |
Primecap Management
Pasadena,
California
|
-$311M |
LLY Hedge Fund Activity: Q3 2021 in Review
2,051 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q3 2021, worth a combined $183B — up 0.58% from $182B a quarter earlier.
Buyers outnumbered sellers: 133 funds opened new LLY positions and 79 closed out — a net gain of 54 holders — while 731 added to existing stakes and 799 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $868M. The largest seller was Wellington Management Group, cutting an estimated $530M.
- 2,051 institutional investors held Eli Lilly (LLY) as of Q3 2021, up from 2,022 in Q2 2021.
- Funds reported $183B of Eli Lilly stock for Q3 2021, up 0.58% quarter-over-quarter.
- 133 funds opened new Eli Lilly positions in Q3 2021 and 79 closed out, a net change of +54 holders.
- The largest Eli Lilly buyer in Q3 2021 was T. Rowe Price Associates, an estimated $868M added.
- The largest Eli Lilly seller in Q3 2021 was Wellington Management Group, an estimated $530M sold.
Based on aggregated 13F filings for Q3 2021.